Zinc supplement for liver scarring in hepatitis B patients
Part of Digestive system, Infections clinical trials.
This trial tests whether adding a zinc supplement to standard hepatitis B treatment can reduce liver scarring (fibrosis) in patients with moderate scarring. It may help improve liver health and prevent further damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have chronic hepatitis B and be taking antiviral medication.
- You must have liver fibrosis stage F2 or F3 (moderate scarring).
- You must not have had a liver transplant or liver cancer.
- You must not be infected with HIV or hepatitis C.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This study tests a new medicine called ZM-H1505R for people with chronic hepatitis B who are already taking standard antiviral therapy. It aims to see if the new drug can help control the infection better.
This trial tests whether a special nutritional supplement can protect the liver in people with chronic hepatitis C. If you have mild to moderate liver damage and meet the criteria, you may be able to join.
This study looks at better ways to predict significant liver fibrosis (scarring) in people with chronic hepatitis B or non-alcoholic fatty liver disease. It aims to help avoid invasive tests like liver biopsy.
Hear when a new Liver Fibroses trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.